Mountain River Pharmaceutical: Net profit is expected to increase by 47.84% compared to 2025, with a proposed dividend of 3 yuan per share.

Shanhe Medicine and Chemical announced its annual report on April 22nd, with an operating income of 943 million yuan in 2025, a year-on-year increase of 6.82%; net profit attributable to shareholders was 177 million yuan, a year-on-year increase of 47.84%; and basic earnings per share were 0.75 yuan. The company plans to distribute a cash dividend of 3 yuan for every 10 shares. During the reporting period, the company deepened the substitution of imported pharmaceutical excipients, with continued growth in sales performance and steady improvement in product quality. New products such as sodium stearoyl lactylate and injectable sodium carboxymethyl cellulose have achieved remarkable results, and the company has achieved outstanding results in expanding overseas markets, with a growth in export sales exceeding 25%. The ongoing investment projects are releasing new production capacity, leading to a steady improvement in gross profit margin.